In vivo activity of perifosine against Leishmania amazonensis
Miltefosine has been established as the first oral administration drug against cutaneous and visceral leishmaniasis. Other alkyl-phospholipids such as edelfosine have been tested against Leishmania showing an in vitro antiparasitic activity. Perifosine in vitro activity has been previously demonstra...
Saved in:
Published in | Acta tropica Vol. 108; no. 1; pp. 20 - 25 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier B.V
01.10.2008
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Miltefosine has been established as the first oral administration drug against cutaneous and visceral leishmaniasis. Other alkyl-phospholipids such as edelfosine have been tested against
Leishmania showing an
in vitro antiparasitic activity. Perifosine
in vitro activity has been previously demonstrated against different
Leishmania species including
Leishmania amazonensis. In this study edelfosine and perifosine were orally administered to
BALB/
c mice at doses of 1 and 2.5
mg/kg/day during 28 days and 5
mg/kg/day during 14 days, starting the treatment 2 weeks after the first treatment scheme. Lesion sizes and parasitic burden as well as viability were determined in order to establish the treatment effectiveness. An assay to compare miltefosine at standard dose of 2.5
mg/kg/day during 28 days to an
in vivo treatment with perifosine at the most effective treatment scheme observed in this study 5
mg/kg/day during 14 days, was also developed. Perifosine showed the higher activity in the
in vivo assay and is showing as a new possibility within the alkyl-phospholipids group for the treatment against cutaneous leishmaniasis caused by
L. amazonensis. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0001-706X 1873-6254 |
DOI: | 10.1016/j.actatropica.2008.08.005 |